Prospective clinical trials comparing selective ERA (inhibition of ETA) head-to-head against dual ERA (combined inhibition of ETA/ETB) therapy at early disease time points may be required to identify a potential advantage of selective ERA therapy in PAH. This evidence concerns the gene EDNRA and pulmonary arterial hypertension.